Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| OB Octarine BioCompany profile Octarine Bio develops bio-based pigments through precision fermentation for textiles and other industrial applications. Octarine Bio develops bio-based pigments through precision fermentation for textiles and other industrial applications. | €5M | Series A extensionSeries A | Biotech | Denmark | Investors | |
| M Develops and commercializes rare disease therapies using AI | $82M | Series A | Biotech | United States | Investors | |
| I InfinitopesCompany profile Develops precision therapeutic vaccines against multiple solid tumour indications Develops precision therapeutic vaccines against multiple solid tumour indications | $15.4M | Seed | Biotech | United Kingdom | Investors | |
| P Provides AI-powered commercial intelligence for Life Sciences organizations | $6M | Seed | Biotech | United States | Investors | |
| TB Think BioscienceCompany profile Develops small molecule drugs for historically challenging drug targets Develops small molecule drugs for historically challenging drug targets | $55M | Series A | Biotech | United States | Investors | |
| E ExcivaCompany profile Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease | €51M | Series B | Biotech | Germany | Investors | |
| B BIOMAKERS analyzes clinical and genomic information. | $8M | Undisclosed | Biotech | United States | Investors | |
| C Cancilico develops AI diagnostic software for hematology. | €2.5M | Seed | Biotech, Healthtech | Germany | Investors | |
| AI Anzen IndustriesCompany profile Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. | $2.2M | Pre-seed | Biotech | United States | Investors | |
| C Develops cell therapy platform for liver disease | $60M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.